Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Synuclere
- Development stage
- Preclinical
- Lead developer
- ProteoTech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Synuclere** is an investigational small molecule developed by ProteoTech for the treatment of Parkinson's disease. It targets alpha-synuclein aggregates, key pathological features in Parkinson's, by inhibiting their formation and promoting disaggregation, aiming to reduce neuronal toxicity and slow disease progression. The drug is in late-stage preclinical development, with no approved status or disclosed mechanism details beyond amyloid targeting.
02
Targets
SNCA (Alpha-synuclein)
Beyond the preview
Go deeper on Synuclere.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Synuclere.